

Selected Innovative Medicines in Development as of October 14, 2025



Oncology (1 of 3)

AKEEGA (niraparib/abiraterone)
M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

IMBRUVICA (ibrutinib)
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

RYBREVANT (amivantamab)
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma TNI (CARTITUDE-5)

ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

JNJ-1900 (NBTXR3)
Head and Neck Cancer

RYBREVANT (amivantamab)
Colorectal Cancer 2L (ORIGAMI-3)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

DARZALEX (daratumumab)
Smoldering Multiple Myeloma (AQUILA)

IMBRUVICA (ibrutinib)
Frontline Mantle Cell Lymphoma (Triangle)

RYBREVANT (amivantamab)
Subcutaneous (PALOMA-3)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

INLEXZO (gemcitabine intravesical system)
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

pasritamig
Prostate Cancer

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

TALVEY (talquetamab)
TIE NDMM in combination with DR (MajesTEC-7)

DARZALEX (daratumumab)
Frontline multiple myeloma transplant ineligible (CEPHEUS)

INLEXZO (gemcitabine intravesical system)
Non Muscle Invasive Bladder Cancer (SunRISe-1)

Bleximenib
Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

INLEXZO (gemcitabine intravesical system)
High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

RYBREVANT (amivantamab)
Colorectal Cancer (ORIGAMI-2)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

TAR-210 (RIS/erdafitinib)
Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3)
TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)
JNJ-1900 (NBTXR3) Lung Cancer
JNJ-0631 (ARX305) Renal Cancer
JNJ-2761 Multiple Myeloma
JNJ-4680 Lung Cancer
JNJ-5322 Multiple Myeloma
JNJ-8177 (ARX517) Prostate Cancer

TECVAYLI (teclistamab) TE NDMM maintenance (MajesTEC-4)
bleximenib Relapsed Refractory Acute Myeloid Leukemia (ALE1001)
TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma (RedirectT-1)
JNJ-1493 Hematological Malignancies
JNJ-3413 Lymphoma
JNJ-4681 Hematological Malignancies
JNJ-6420 Prostate Cancer
JNJ-8377 Lymphoma

TECVAYLI (teclistamab) TIE NDMM in combination with DR (MajesTEC-7)
JNJ-0683 (ARX788) Breast Cancer
JNJ-0387 Solid Tumors
JNJ-2638 Gastrointestinal Cancer
JNJ-4496 Hematological Malignancies
JNJ-4916 Lung Cancer
JNJ-7446 Lung Cancer
JNJ-8543 Hematological Malignancies

Oncology (3 of 3)

JNJ-9401
Prostate Cancer

JNJ-9968
Hematological Malignancies

JNJ-9530
Hematological Malignancies

JNJ-9892
Hematological Malignancies

icotrokinra Psoriasis (ICONIC)	SIMPONI (golimumab) Pediatric Ulcerative Colitis (PURSUIT 2)	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)
STELARA (ustekinumab) Pediatric Juvenile Psoriatic Arthritis	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis	icotrokinra Psoriatic Arthritis
nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)	nipocalimab Sjogren's Disease	nipocalimab Hemolytic Disease of the Fetus and Newborn (AZALEA)
nipocalimab Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)	STELARA (ustekinumab) Pediatric Ulcerative Colitis (UNIFI JR)	TREMFYA (guselkumab) Pediatric Crohn's Disease (MACARONI-23)
TREMFYA (guselkumab) Pediatric Ulcerative Colitis (QUASAR JR)	icotrokinra Ulcerative Colitis	JNJ-4804 Co-antibody Therapy Ulcerative Colitis
JNJ-4804 Co-antibody Therapy Psoriatic Arthritis	JNJ-4804 Co-antibody Therapy Crohn's Disease	JNJ-5939 Atopic Dermatitis
nipocalimab Systemic Lupus Erythematosus	nipocalimab Idiopathic Inflammatory Myopathy	JNJ-5108 Immunological Diseases

JNJ-6848
Immunological Diseases

JNJ-7528
Atopic Dermatitis

CAPLYTA (lumateperone)
Adjunctive Treatment for Major Depressive Disorder

SPRAVATO (esketamine)
Treatment Resistant Depression monotherapy (TRD4005)

nipocalimab
Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

ITI-1284
Generalized Anxiety Disorder

JNJ-1887 sCD59
Geographic Atrophy

posdinemab
Alzheimer's Disease (AUTONOMY)

IMAAVY (nipocalimab)
Generalized Myasthenia Gravis (Vivacity MG3)

CAPLYTA (lumateperone)
Bipolar Mania

RPGR Gene Therapy
Retinitis Pigmentosa (LUMEOS)

ITI-1284
Alzheimer's Disease-Related Psychosis

JNJ-2056 (tau active immunotherapy) *
Alzheimer's Disease (RETAIN)

SPRAVATO (esketamine)
Major Depressive Disorder with Suicidal Ideation
Pediatrics

IMAAVY (nipocalimab)
Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

CAPLYTA (lumateperone)
Pediatric Psychiatric Indications

seltorexant
Adjunctive Treatment for Major Depressive Disorder with
Insomnia Symptoms (OARS)

ITI-1284
Alzheimer's Disease-Related Agitation

JNJ-5120
Major Depressive Disorder

Select Other Areas

CABENUVA

HIV Adolescents

milvexian (Factor Xla)

Secondary Stroke Prevention

SIRTURO

Leprosy

UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

milvexian (Factor Xla)

Acute Coronary Syndrome

SIRTURO

Tuberculosis Long Acting

macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

milvexian (Factor Xla)

Atrial Fibrillation

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKT1: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited